TTD | Drug: D03TYJ

Drug General Information
Drug ID	D03TYJ
Former ID	DIB008589
Drug Name	ATHX-105
Synonyms	ATH-88651; 5-HT2c receptor agonists (obesity), Athersys Inc
Indication	Obesity [ICD9: 278; ICD10:E66]		Phase 2	[522405]
Company	Athersys
Target and Pathway
Target(s)	5-hydroxytryptamine 2C receptor	Target Info	Agonist	[544074]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Gap junction
	Serotonergic synapse
	Inflammatory mediator regulation of TRP channels
PANTHER Pathway	5HT2 type receptor mediated signaling pathway
Reactome	Serotonin receptors
Reactome	G alpha (q) signalling events
WikiPathways	Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 522405	ClinicalTrials.gov (NCT00735683) A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety. U.S. National Institutes of Health.
Ref 544074	Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information